Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MYB | P10242 | 13/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4343035 | 0.92 | MYB (0.53) | MAPK1HSD17B10MYB | |
| SCHEMBL4334030 | 0.87 | MYB (0.49) | MAPK1HSD17B10MYBL3MBTL1ALDH1A1 | |
| SCHEMBL4328192 | 0.87 | MYB (0.50) | MYBL3MBTL1KDM4EMEN1MAPT | |
| SCHEMBL4341245 | 0.86 | NPC1 (0.55) | MAPK1MYBL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL4334495 | 0.86 | MYB (0.48) | MYBL3MBTL1ALDH1A1KDM4EMAPT | |
| SCHEMBL4334348 | 0.86 | MEN1 (0.55) | MYBL3MBTL1KDM4EMEN1MAPT | |
| SCHEMBL4330101 | 0.84 | MYB (0.67) | MYBSMN1; SMN2RAB9A | |
| SCHEMBL4329068 | 0.82 | MYB (0.53) | MYBMEN1KMT2A | |
| SCHEMBL4320218 | 0.82 | MYB (0.53) | HSD17B10MYBL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL4323526 | 0.82 | MYB (0.68) | MYBL3MBTL1ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528164-B2 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-05-05 | — | — | US | claimed |
| US-20060104998-A1 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-18 | — | — | US | claimed |
| US-7528164-B2 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7235674-B2 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060104998-A1 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-7015328-B2 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050090526-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-04-28 | — | — | US | disclosed |
| US-20030114485-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060104998-A1 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP4, CASP2 | MAPK1 2113/4885HSD17B10 799/4885MYB 326/4885 |
| US-20030114485-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, CASP1, CASP5 | MAPK1 611/4885HSD17B10 1248/4885MYB 1001/4885 |
| US-20050090526-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, CASP5, CASP14 | MAPK1 994/4885HSD17B10 1178/4885MYB 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.